Pattern of Use of β-Blockers in Older Patients with Stable Coronary Artery Disease

Drugs & Aging ◽  
2011 ◽  
Vol 28 (9) ◽  
pp. 703-711 ◽  
Author(s):  
Cristiana Vitale ◽  
Ilaria Spoletini ◽  
Maurizio Volterrani ◽  
Ferdinando Iellamo ◽  
Massimo Fini
2019 ◽  
Vol 40 (18) ◽  
pp. 1399-1407 ◽  
Author(s):  
Emmanuel Sorbets ◽  
Philippe Gabriel Steg ◽  
Robin Young ◽  
Nicolas Danchin ◽  
Nicola Greenlaw ◽  
...  

Author(s):  
Inga Balode ◽  
Sanda Jēgere ◽  
Iveta Mintāle ◽  
Inga Narbute ◽  
Gustavs Latkovskis ◽  
...  

Heart rate and other risk factors in outpatients with stable coronary artery disease in Latvia The aim of the study was to characterise coronary artery disease (CAD) outpatients in Latvia by risk factors (RF) including heart rate (HR), physical examination data, clinical data and treatment. Twelve practitioners had each examined and questioned 6 to 12 patients with established CAD (n = 120). The most frequent cardiovascular (CV) RF and co-morbidity were dyslipidemia (94.2%) and hypertension (78.3%), respectively. Prevalence of increased resting HR (≥70 bpm) was 35.9% and 33.6%, when measured by pulse palpation and electrocardiography, respectively. Regarding other RFs, prevalence of treated but insufficiently controlled blood pressure 140/90 mmHg, total cholesterol 1 > 5 mmol/l and triglycerides > 1.7 mmol/l was 25.8%, 30.1% and 33.3%, respectively. Aspirin, statins and angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers were used in 96.7%, 94.2% and 85.0% of cases, respectively. Beta blockers were used in 81.7% of cases. Average daily doses of most frequently used β blockers (metoprolol and bisoprolol) were 32% and 53% from target doses, respectively. In three cases β blockers were combined with ivabradin. Our results suggest that practitioners follow guidelines and consider CV prevention by treating CAD patients. Our data identified, however, unused potential for better control of increased HR by higher doses and combinations of HR-reducing agents.


Diabetes ◽  
1997 ◽  
Vol 46 (9) ◽  
pp. 1491-1496 ◽  
Author(s):  
M. Maki ◽  
P. Nuutila ◽  
H. Laine ◽  
L. M. Voipio-Pulkki ◽  
M. Haaparanta ◽  
...  

2020 ◽  
Vol 27 (7) ◽  
pp. 1052-1080 ◽  
Author(s):  
Evangelos Oikonomou ◽  
Gerasimos Siasos ◽  
Vasiliki Tsigkou ◽  
Evanthia Bletsa ◽  
Maria-Evi Panoilia ◽  
...  

Coronary artery disease is the leading cause of morbidity and mortality worldwide. The most common pathophysiologic substrate is atherosclerosis which is an inflammatory procedure that starts at childhood and develops throughout life. Endothelial dysfunction is associated with the initiation and progression of atherosclerosis and is characterized by the impaired production of nitric oxide. In general, endothelial dysfunction is linked to poor cardiovascular prognosis and different methods, both invasive and non-invasive, have been developed for its evaluation. Ultrasound evaluation of flow mediated dilatation of the branchial artery is the most commonly used method to assessed endothelial function while intracoronary administration of vasoactive agents may be also be used to test directly endothelial properties of the coronary vasculature. Endothelial dysfunction has also been the subject of therapeutic interventions. This review article summarizes the knowledge about evaluation of endothelial function in acute coronary syndromes and stable coronary artery disease and demonstrates the current therapeutic approaches against endothelial dysfunction.


Sign in / Sign up

Export Citation Format

Share Document